DEUCRAVACITINIB for Dermatitis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 5 adverse event reports in the FDA FAERS database where DEUCRAVACITINIB was used for Dermatitis.
Most Reported Side Effects for DEUCRAVACITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 228 | 9.6% | 0 | 1 |
| Acne | 225 | 9.4% | 0 | 1 |
| Pruritus | 187 | 7.8% | 0 | 2 |
| Rash | 175 | 7.3% | 0 | 0 |
| Erythema | 124 | 5.2% | 0 | 2 |
| Psoriasis | 122 | 5.1% | 0 | 2 |
| Off label use | 101 | 4.2% | 1 | 6 |
| Adverse event | 74 | 3.1% | 0 | 0 |
| Mouth ulceration | 72 | 3.0% | 0 | 1 |
| Folliculitis | 65 | 2.7% | 0 | 2 |
| Headache | 65 | 2.7% | 0 | 0 |
| Product dose omission issue | 61 | 2.6% | 0 | 0 |
| Pain | 60 | 2.5% | 0 | 1 |
| Skin burning sensation | 60 | 2.5% | 0 | 1 |
| Diarrhoea | 46 | 1.9% | 1 | 3 |
Other Indications for DEUCRAVACITINIB
Psoriasis (1,456)
Product used for unknown indication (808)
Psoriatic arthropathy (41)
Eczema (10)
Pustular psoriasis (10)
Guttate psoriasis (9)
Dermatitis atopic (8)
Palmoplantar pustulosis (6)
Erythrodermic psoriasis (5)
Granuloma annulare (5)
Other Drugs Used for Dermatitis
DUPILUMAB (9,959)
CRISABOROLE (407)
APREMILAST (122)
TRALOKINUMAB-LDRM (90)
KETOCONAZOLE (66)
CYCLOSPORINE (62)
DOXYCYCLINE (57)
PIMECROLIMUS (55)
CLOBETASOL (50)
RUXOLITINIB (50)